Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 12, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

February 1, 2025

Conditions
Cancer of Stomach, AdenocarcinomaAscites, Malignant
Interventions
DRUG

zoledronic acid plus Sintilimab intraperitoneal injection

At D-5\~D-1, drain the ascites by placing a tube in the abdominal cavity first, try to drain the ascites as much as possible according to the clinical routine, and record the amount of drainage.D1, D8, D15, D22 start the first immunocheckpoint inhibitor combined with zoledronic acid treatment, try to drain the ascites first, calculate the amount of drugs according to the patient's body weight, and then dissolve the corresponding dosage of immunocheckpoint inhibitor and zoledronic acid in 100 ml of saline and inject them into the abdominal cavity respectively, and then inject another 100 ml of saline according to the patient's tolerance. The corresponding dose of immune checkpoint inhibitor and zoledronic acid was dissolved in 100 ml of saline and injected into the abdominal cavity.

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Qilu Hospital of Shandong University

OTHER